JO
Rating #113
Johnson & Johnson
Portfolio value
Stocks
Performance
1 Year
+22.55%
Stock Holdings
$
%
1Y
3Y
5Y
10Y
Top10 stocks: 97.20% of the portfolio
Adds
New Buys
Sold Outs
Cuts
No trading activity
Company Name | Primary Industry | Avg. price paid | Share Count Chg. (%) | No of shares held | Market value | Portfolio % Change | % of Ownership | Holding period | Last Transaction | |
|---|---|---|---|---|---|---|---|---|---|---|
1 ![]() PTGX | Pharmaceutical Pres | $17.72 | 0.00% | 2.45M | $162.70M | 32.30% -8.52ppt | 3.86% | 17 Quarters | Q3 2021 | |
2 ![]() NBTX | Pharmaceutical Pres | $7.53 | 0.00% | 5.62M | $106.23M | 21.09% 13.47ppt | 11.86% | 9 Quarters | Q4 2023 | |
3 ![]() MGTX | Biological products | $9.43 | 0.00% | 6.64M | $54.66M | 10.85% -2.29ppt | 8.24% | 17 Quarters | Q4 2022 | |
4 ![]() RAPP | Pharmaceutical Pres | $25.44 | -28.56% | 1.78M | $53.00M | 10.52% 1.98ppt | 0.50% | 6 Quarters | Q3 2025 | |
5 ![]() CVRX | Surgical Instruments | $16.75 | 0.00% | 4.10M | $33.11M | 6.57% -0.57ppt | 15.74% | 17 Quarters | Q1 2024 | |
6 ![]() LEGN | Pharmaceutical Pres | $50.56 | 0.00% | 814.59K | $26.56M | 5.27% -3.17ppt | 0.88% | 17 Quarters | Q2 2023 | |
7 ![]() CTNM | Pharmaceutical Pres | $21.00 | 0.00% | 1.98M | $23.26M | 4.62% 2.18ppt | 7.64% | 6 Quarters | Q2 2024 | |
8 ![]() PRCT | Surgical Instruments | $38.15 | 0.00% | 357.94K | $12.77M | 2.54% -3.56ppt | 0.65% | 17 Quarters | Q4 2022 | |
9 ![]() XNCR | Pharmaceutical Pres | $40.12 | 0.00% | 748.06K | $8.77M | 1.74% -0.08ppt | 1.01% | 16 Quarters | Q4 2021 | |
10 ![]() ARWR | Pharmaceutical Pres | $62.43 | 0.00% | 247.60K | $8.54M | 1.70% 0.50ppt | 0.18% | 17 Quarters | Q3 2022 | |
11 ![]() FATE | Biological products | $59.27 | 0.00% | 3.38M | $4.26M | 0.85% -0.21ppt | 2.85% | 17 Quarters | Q3 2021 | |
12 ![]() NMRA | Biological products | $15.60 | 0.00% | 1.85M | $3.37M | 0.67% 0.25ppt | 1.14% | 9 Quarters | Q4 2023 | |
13 ![]() VOR | Biological products | $48.72 | +100.00% | 53.73K | $2.62M | 0.52% 0.52ppt | 0.80% | 1 Quarter | Q3 2025 | |
14 R RLYB | Pharmaceutical Pres | $1.36 | 0.00% | 3.64M | $1.81M | 0.36% -0.00ppt | 8.11% | 6 Quarters | Q2 2024 | |
15 ![]() LYEL | Pharmaceutical Pres | $16.24 | +100.00% | 41.17K | $668.52K | 0.13% 0.13ppt | 0.28% | 1 Quarter | Q3 2025 | |
16 ![]() NNOX | X-Ray Apparatus | $11.10 | 0.00% | 158.85K | $587.75K | 0.12% -0.13ppt | 0.25% | 16 Quarters | Q1 2024 | |
17 ![]() LAB | Lab Analytical Instruments | $2.70 | 0.00% | 311.97K | $405.56K | 0.08% -0.03ppt | 0.08% | 7 Quarters | Q1 2024 | |
18 A ACET | Pharmaceutical Pres | $7.84 | 0.00% | 364.47K | $295.30K | 0.06% -0.01ppt | 0.40% | 17 Quarters | Q1 2024 | |
19 ![]() PHGE | Biological products | $3.06 | 0.00% | 96.87K | $50.86K | 0.01% -0.00ppt | 0.31% | 17 Quarters | Q4 2024 | |
20 S SENS | Industrial Instruments | $3.39 | 0.00% | 54.62K | $23.80K | 0.01% -0.00ppt | 0.01% | 17 Quarters | Q3 2021 |
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.